The U.K. government agreed to loosen drug-price controls and increase medicine spending in return for a three‑year exemption from potential U.S. tariffs on British pharmaceuticals under Section 232. The deal raises NICE’s cost‑effectiveness thresholds and reduces mandated manufacturer rebates to NHS England, changes that officials say will enable 3–5 additional drug approvals per year. In exchange, the U.S. will refrain from imposing tariffs on U.K.-origin drugs, active pharmaceutical ingredients and devices for three years—an accord intended to protect U.K. life‑science investment while altering price‑setting norms domestically.